CoChat

Treatment with Next-Generation ALK Inhibitors Fuels Plasma ALK Mutation Diversity

Open access
Dagogo-Jack, Ibiayi, Rooney, Marguerite, Lin, Jessica J., Nagy, Rebecca J., Yeap, Beow Y., Hubbeling, Harper, Chin, Emily, Ackil, Jennifer, Farago, Anna F., Hata, Aaron N., Lennerz, Jochen K., Gainor, Justin F., Lanman, Richard B., Shaw, Alice T. · 2019 · Clinical Cancer Research
Cited by 149

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

Purpose: Acquired resistance to next-generation ALK tyrosine kinase inhibitors (TKIs) is often driven by secondary ALK mutations. Here, we investigated utility of plasma genotyping for identifying ALK resistance mutations at relapse on next-generation ALK TKIs. Experimental Design: We analyzed 106 plasma specimens from 84 patients with advanced ALK-positive lung cancer treated with second- and third-generation ALK TKIs using a commercially available next-generation sequencing (NGS) platform (Guardant360). Tumor biopsies from TKI-resistant lesions underwent targeted NGS to identify ALK mutations. Results: By genotyping plasma, we detected an ALK mutation in 46 (66%) of 70 patients relapsing on a second-generation ALK TKI. When post-alectinib plasma and tumor specimens were compared, there was no difference in frequency of ALK mutations (67% vs. 63%), but plasma specimens were more likely to harbor ≥2 ALK mutations (24% vs. 2%, P = 0.004). Among 29 patients relapsing on lorlatinib, plasma genotyping detected an ALK mutation in 22 (76%), including 14 (48%) with ≥2 ALK mutations. The most frequent combinations of ALK mutations were G1202R/L1196M and D1203N/1171N. Detection of ≥2 ALK mutations was significantly more common in patients relapsing on lorlatinib compared with second-generation ALK TKIs (48% vs. 23%, P = 0.017). Among 15 patients who received lorlatinib after a second-generation TKI, serial plasma analysis demonstrated that eight (53%) acquired ≥1 new ALK mutations on lorlatinib. Conclusions: ALK resistance mutations increase with each successive generation of ALK TKI and may be underestimated by tumor genotyping. Sequential treatment with increasingly potent ALK TKIs may promote acquisition of ALK resistance mutations leading to treatment-refractory compound ALK mutations.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-19-1436

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 149

Metadata

Authors
Dagogo-Jack, I., Rooney, M., Lin, J. J., Nagy, R. J., Yeap, B. Y., Hubbeling, H., Chin, E., Ackil, J., Farago, A. F., Hata, A. N., Lennerz, J. K., Gainor, J. F., Lanman, R. B., & Shaw, A. T.
Venue
Clinical Cancer Research
Published
2019-11-15
Volume
25
Issue
22
Pages
6662-6670
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2966785785
Cited by
149
References
9
FWCI
14.99
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Treatment with Next-Generation ALK Inhibitors Fuels Plasma ALK Mutation Diversity. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-19-1436
The paper
Dagogo-Jack, I., Rooney, M., Lin, J. J., Nagy, R. J., Yeap, B. Y., Hubbeling, H., Chin, E., Ackil, J., Farago, A. F., Hata, A. N., Lennerz, J. K., Gainor, J. F., Lanman, R. B., & Shaw, A. T. (2019). Treatment with Next-Generation ALK Inhibitors Fuels Plasma ALK Mutation Diversity. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-19-1436

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.